GPT and type 2 diabetes mellitus: It has been reported that “higher liver transaminase levels are associated with oral hypoglycemic agent failure” and that the relative risk for oral antidiabetic therapeutic failure falls by 1.7 for every 5-U decrease in ALT levels.11 Based on this relationship, our results indicate a 2.2-fold decrease in relative risk of therapeutic failure in T2D subjects receiving oral hypoglycemic agents with the consumption of NFC.